Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III induction study of afimkibart in moderately to severely active ulcerative colitis
2024-513015-27-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Afimkibart with Placebo (2 arms). Primary endpoint: Clinical remission at Week 12. Planned start Nov 2024; status: authorised.
02
Drugs
afimkibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2024-513015-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513015-27-00.